sábado, 7 de noviembre de 2026
BuscarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· June 16, 2026

Defiance ETFs Mengumumkan Penyambungan Semula Dagangan bagi Defiance Daily 2X Space ETF (SPCL) di Cboe BZX Exchange, Inc.

View original at globenewswire.com
Defiance ETFs Mengumumkan Penyambungan Semula Dagangan bagi Defiance Daily 2X Space ETF (SPCL) di Cboe BZX Exchange, Inc. MIAMI, June 17, 2026 (GLOBE NEWSWIRE) -- Defiance ETFs, peneraju dalam dana dagangan bursa bertema dan berleveraj, hari ini mengumumkan bahawa Cboe BZX Exchange, Inc…
Opening lines of the source · short snapshot — read the full document at the original

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • SpaceX risks include new or unproven technology programs such as Starship, next-generation Starlink satellites, and orbital AI initiatives

    60% confidence
  • Cboe BZX Exchange has approved the resumption of trading in SPCL shares following the temporary suspension initiated by the Exchange on June 12, 2026

    60% confidence
  • The SpaceX IPO constitutes a Material Space Event as defined in the amended Prospectus, which will cause the fund to hold all or a significant portion of its portfolio in instruments providing exposure to SpaceX shares

    60% confidence
  • Throughout the suspension period, the underlying portfolio assets remained secure and were unaffected by the trading suspension imposed by the Exchange

    60% confidence
  • Defiance pioneered single-stock leveraged ETFs, allowing investors to take amplified positions in high-potential companies with precise leveraged exposure without opening a margin account

    60% confidence
  • For periods longer than one day, the fund's performance will be the result of compounded daily returns, which will almost certainly differ from 200% of the Target Portfolio's return over the same period

    60% confidence
  • The derivatives market (swaps, options) for SpaceX as a newly listed company may be limited, illiquid, highly volatile, expensive, or unavailable, which could increase tracking error or prevent the fund from achieving its investment objective

    60% confidence
  • SpaceX is expected to be a controlled company with voting power concentrated in founder Elon Musk through Class B common shares carrying 10 votes per share

    60% confidence
  • SPCL's investment in SpaceX exposure relies on derivatives (swap agreements and listed option contracts) rather than directly holding underlying securities

    60% confidence
  • The fund is intended for knowledgeable investors who understand the implications of seeking leveraged daily (2X) investment results and are prepared to monitor their portfolios frequently; it is not suitable for investors who do not intend to actively monitor and manage their portfolios

    60% confidence
  • The fund's investment results following a rebalancing in response to a Material Space Event may differ materially from prior results, and the fund may temporarily deviate from its targeted daily exposure level

    60% confidence
  • SPCL seeks daily investment results equal to 200% of the daily performance of its Target Portfolio

    60% confidence
  • An investor could lose the entire value of their principal investment in a single trading day

    60% confidence

Data points we hold from this source

Elon Musk · parameter count10 votes_per_Class_B_share
Lo que sabemos · la inteligencia detrás de esta página
En vivo desde el sustrato
Lo que estamos viendo
Q4 2026 Biotech Catalyst Season: Regulatory Deadlines and Data Readouts Against Cost Discipline and Slipping Timelines
From late October 2026 to January 2027, mid-cap biotechs cluster pivotal data presentations (ESMO, AHA, AASLD), FDA decision dates (ivonescimab BLA on 2026-11-14, lorundrostat on 2026-12-22) and Q3 earnings. Alongside these, several companies are managing capital: lowering R&D and SG&A guidance, pushing clinical milestones into 2027, authorizing a $400M buyback, and pursuing a delisting. Late-stage programs in oncology, hepatitis delta, hypertension and women's health look near commercial inflection, while cost cuts and delays point to uneven balance-sheet strength.
Nuestra lectura de los datos ›
Señales que seguimos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patrones que observamos ›
Donde las fuentes discrepan
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
Señalamos los conflictos abiertamente ›
Verificado recientemente
✓ Verificado con la fuente original
4,996
hechos rastreados a su fuente — y señalamos los que no se sostienen.
101 entidades seguidas4,996 hechos verificados con la fuente5,552 documentos fuente archivados
Consulta estos datos → isubstrate.com
Defiance ETFs Mengumumkan Penyambungan Semula Dagangan bagi Defiance Daily 2X Space ETF (SPCL) di Cboe BZX Exchange, Inc. — Source | Via News | es.VIA.NEWS